A Study of SGN-ALPV in Advanced Solid Tumors

NCT05229900 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Study closed due to portfolio prioritization

Conditions

Ovarian Neoplasms
Endometrial Neoplasms
Carcinoma, Non-Small-Cell Lung
Stomach Neoplasms
Gastroesophageal Junction Carcinoma
Uterine Cervical Neoplasms
Testicular Neoplasms

Interventions

DRUG: SGN-ALPV

Sponsor

Seagen Inc.